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Abstract
Introduction
Dopamine transporter scans are increasingly being used in the diagnosis of clinically
undefined Parkinsonism.
Aims
To assess the indications for imaging usage and its impact on future clinical management.
Methods
Retrospective review of scans ordered and their corresponding results over a five-year period.
A chart review was carried out on a cohort of scans to assess changes in clinical management.
Results
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One hundred and eighty scans (69% of total) were reported as showing evidence of
dopaminergic deficit. A chart review in 81 patients showed a change in clinical management in
53 patients (65%). Scans were ordered inappropriately in 34 patients (13%).
Discussion
123I-FP-CIT SPECT scans are being more frequently ordered and if used correctly can alter
clinical management. Increased education on indications for use is required to reduce waste of
resources and risk to patients.
Introduction
Parkinson disease (PD) is the second most common neurodegenerative disease and is characterised by
the presence of bradykinesia plus one of rigidity, tremor, or postural instability . Misdiagnosis rates from
10 to 50% have been found using clinical exam alone, when compared to the gold standard pathological
diagnosis . The most common PD mimics include tremor disorders, drug-induced Parkinsonism,
vascular Parkinsonism and Parkinson plus conditions. The prognosis and management of each disorder
differs significantly from PD, and from each other. Therefore, the ability to distinguish between different
parkinsonian entities is of clinical importance, allowing for optimal treatment and avoiding unnecessary
therapeutic trials or other tests.
In-vivo functional imaging of dopamine transporters (DAT) can improve diagnostic accuracy in atypical
cases of Parkinsonism. DaTSCAN, which is the trade name for striatal presynaptic dopamine transporter
imaging using 123I-FP-CIT [(123)I-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-nortropane] Single
Photon Emission Computed Tomography [SPECT], has been licensed by the European Medicines
Agency (EMA), The Society of Nuclear Medicine (SNM) and the US Food and Drug Administration (FDA)
for certain indications (figure 1) . Reductions in 123I-FP-CIT SPECT striatal uptake is demonstrated to
have 95% sensitivity and 95% specificity with a high positive predictive value for identifying parkinsonian
syndromes (PS) . 123I-FP-CIT SPECT initial imaging results have been remarkably consistent with the
clinical diagnoses made at three years follow-up . Almost 100% concordance has been found between
neuroradiologists on interpreting this imaging . The PS which include PD, Multiple system Atrophy
(MSA), Progressive supranuclear palsy (PSP) and Corticobasal degeneration (CBD) show nigrostriatal
degeneration on DAT neuroimaging. Other conditions, such as essential or (ET), drug-induced
Parkinsonism (DIP), vascular parkinsonism (VP), psychogenic parkinsonism, normal aging, normal
pressure hydrocephalus and dystonic tremor may demonstrate features of parkinsonism, but do not have
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nigrostriatal degeneration on neuroimaging . In the appropriate clinical setting (such as where the
differential diagnoses being queried include a neurodegenerative Parkinsonism versus another mimic
disorder), 123I-FP-CIT SPECT can be a very useful investigation. However, as each scan costs
approximately €1,200 per patient, this is a resource that should not be used routinely.
Our primary aim was to evaluate the current use of 123I-FP-CIT SPECT in our health service as a
diagnostic biomarker for parkinsonian syndromes. We reported on the indications for ordering 123I-FP-
CIT SPECT along with assessing trends of referral by different specialties. We investigated for
correlations between dopaminergic deficit on imaging and demographics or symptomatology. We
identified inappropriate referrals and assessed the impact of these scans on subsequent clinical
management.
Methods
Study design: A retrospective review of 123I-FP-CIT SPECT request forms and their corresponding
results over a five-year period from 2008-2013 in two tertiary care hospitals, Cork University Hospital
[CUH], Cork, Ireland and University Hospital Limerick [UHL], Limerick, Ireland. Patients in two tertiary
care hospitals who underwent 123I-FP-CIT SPECT over this five-year period were included in the study.
No additional exclusion or inclusion criteria were applied. Scans were carried out as per each institution’s
protocol and in accordance with international guidelines. Patients were instructed to discontinue all
potential confounding medications prior to scan. All scans were read by experienced radiologists who
were aware of clinical history and differential diagnoses as documented on referral. Demographics
including gender, age at scan, symptoms, medications and scan report details including indication for
DaTSCAN, referring specialty and institution were manually gathered. Inappropriate referrals were
defined as referral indications not approved by FDA, SNM or EMA guidelines and included differentiating
PD from other PS, dystonia, vascular parkinsonism, dementia and unknown along with assessing
progression (see table 1 for recommended indications for DaTSCAN). We reviewed all available
handwritten charts in our two hospitals in order to evaluate the utility of scans for future clinical
management.
Study Ethics was received from both the Clinical Research Ethics Committee of the Cork Teaching
Hospitals and the Research Ethics Committee of UHL prior to the initiation of the study. Data was inputted
into SPSS version 20. Two groups were formed for statistical analysis: those with and without
dopaminergic deficits. Descriptive statistics, frequencies along with Pearson’s chi-squared test were used.
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Results
Patient demographics and referral sources
Two hundred and sixty-one patients underwent 123I-FP-CIT SPECT over a five-year period. One hundred
and forty-eight (56.7%) were male and median age was 67 years (table 2). The number of scans ordered
increased every year with the most scans completed in the final full calendar year. Scans were
predominantly ordered by neurologists (54.4%), geriatricians (34.5%) and psychiatrists (6.1%). Thirteen
scans were referred from other specialties including general medicine (n=6), rheumatology (n=2),
respiratory (n=1), nephrology (n=1), gastroenterology (n=1) and emergency department (n=1). Fifty-five
percent (55%) of scans were outside referrals, ordered by physicians working outside of our two
hospitals.
Referral reason
The most common reason for ordering a scan was for assessment of a parkinsonian syndrome (PS),
accounting for 62.5% of referrals. Other frequent referral reasons were differentiating drug-induced
Parkinsonism (DIP) from PS at 17.2% and PS vs. PD at 7.3%. Inappropriate referrals were seen in 13%
of cases (table 3).
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Symptomatology
We were interested in the documentation of Parkinsonism, in particular the symptoms needed for The
United Kingdom Parkinson’s Disease Society Brain Bank Clinical Diagnostic (UKPDSBB) criteria . One
hundred and thirty-three patients (51%) had a tremor, 88 patients (33.7%) had rigidity, 69 patients
(26.4%) had bradykinesia and 5 patients (1.9%) had postural instability documented on their request
forms for imaging.
123I-FP-CIT SPECT results and subgroup analysis
One hundred and eighty patients (69%) had positive scans with dopaminergic deficit qualitatively
assessed. Seventy-seven (42.7%) of these scans showed correct laterality between symptom sidedness
and dopaminergic deficit on imaging. Thirty-two scans (17.9%) showed bilateral dopaminergic deficits in
the presence of unilateral symptoms. Twenty-one scans (11.8%) showed dopaminergic deficit on the
incorrect side to unilateral symptoms. In the remaining fifty scans (27.5%), the symptom sidedness was
not documented on the referral forms. When comparing the demographics and symptomatology of those
with evidence of dopaminergic deficit against those with a normal scan, no statistically significant
difference was found regarding age, gender, indication for scan or symptoms.
Change of management
This was assessed by review of handwritten medical notes available in our two hospitals. Eighty-one
charts were available for review. Forty-three (53%) of these scans were ordered by neurologists; 25
(30.9%) ordered by geriatricians; 7 (8.6%) ordered by psychiatrists and 6 (7.4%) ordered by general
medical physicians. Documentation of further management was noted in 53 of these charts (65.4%).
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Twenty-four patients (29.6%) had a change of diagnosis from ET or DIP and PS. Seventeen patients
(21%) were started on new medications including levodopa or anticholinergics, or had an increase in
medication doses after confirmation of diagnosis. Eleven patients (13.5%) had either discontinued
treatment or didn’t start planned medication.
In regards to specialties, changes in management were noted in 65.9% of neurology (27 patients), 94.7%
of geriatrics (18 patients), 50% of psychiatry (2 patients), and 100% of general medicine (6 patients)
referrals.
Discussion
Over the five-year period the number of scans ordered almost quadrupled, from 21 scans in the first year
to 79 in the final year. We think this reflects the increased awareness of the utility of 123I-FP-CIT SPECT
in diagnosing parkinsonian syndromes. Many of our patients (62.5%) were referred for this scan in cases
of PS, although it was often unclear from the referral forms what other diagnoses were being considered
in addition to PS. The second most common indication was for DIP (17.2%). DIP is important to identify
as withdrawal of the offending drug can reverse the symptoms of parkinsonism . 123I-FP-CIT SPECT
scans are ideal for these patients as neuroleptics predominantly affect the postsynaptic dopamine
receptors with only a negligible affinity for the dopamine transporter (DAT) . Interestingly, 26 patients
prescribed neuroleptics were found to have evidence of dopaminergic deficit on neuroimaging. This has
been reported before with antidopaminergic drugs felt to unmask prematurely presymptomatic PD .
Inappropriate referrals for 123I-FP-CIT SPECT are important to identify and prevent as they are a waste
of resources and cause an unnecessary risk to patients without benefit . We found inappropriate
referrals in 34 cases (13% of total) resulting in an estimated cost of €48,000 euros to the health service.
Documented reasons for ordering the scan included differentiating PS from PD; PD from dystonia; PD
from dementia with lewy bodies or assessing progression in PD. Although ongoing research is
investigating variant mapping techniques of 123I-FP-CIT SPECT and other biomarkers for these
reasons , they are currently not clinical indications for the scan and are not licensed by the EMA, SNM
and FDA guidelines (table 1). Positive scans (i.e. evidence of qualitative dopaminergic deficit) were seen
in 69% of cases. We noted a slight trend to a higher proportion of positive scans in the under 60 age
group versus the over 60 age group, at 76% versus 66.1% (p = 0.118), which has been reported
previously . Although not studied in our study, there is an age-related decline of radiotracer uptake in
normal patients of 3.3 to 10% per decade , making the interpretation of results in an older age group
more difficult. Eighty-one scans (31%) were normal with no evidence of dopaminergic deficit. Possible
diagnoses for normal scans include ET, dystonia, dementia not related to Lewy body disease, vascular
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parkinsonism, DIP and psychogenic parkinsonism.
As 55% of patients were referred from outside institutions, we were limited in our chart review. However,
we were able to assess change of management in patients under the care of neurologists, geriatricians,
psychiatrists and general medical physicians. A change in management after 123I-FP-CIT SPECT was
clearly documented in 65.4% of our chart review subgroup. This was consistent with a recent multicentre,
open, non-randomized study which showed change in planned management in 72% of their patients after
DaTSCAN . Another retrospective review, reported a change in management in 63% of cases .
Interestingly in three of our patients, the scans results were not accepted by the ordering physician
suggesting some uncertainty in the scan’s validity.
The overdiagnosis of PD at initial presentation occurs in 10 to 47% of patients in both community and
hospital settings . This misdiagnosis of PD is more likely with non-specialists compared to Movement
disorder experts . In our study, only three scans were requested by a recently appointed Movement
disorder specialist. Prior research had scans ordered solely by neurologists . However, patients with
parkinsonism can present to any specialty and the feasibility and cost-effectiveness of restricting the
ordering of these scans to only neurologists is debatable .
Given the retrospective nature of the study, the large percentage of outside referrals to our centers for
these scans and the reliance on handwritten scan request forms and chart reviews for data collection
there were some limitations to our study. In particular, we were only able to assess change of
management in one-third of scans due to either unclear documentation or inability to access the
handwritten medical records.
Accurate clinical diagnosis in patients with Parkinsonism can often be challenging, especially early in the
disease when signs are minimal; when atypical features are present or when there are other
comorbidities. Dopamine transporter imaging can assist with diagnosis provided it is used for the correct
indications. In our study we showed an increased awareness and utility of dopamine transporter scans in
diagnosing parkinsonian syndromes in our health service. We also identified a significant number of
inappropriate referrals which will be important to address in the future through education or strict
indications on scan request forms in order to reduce the waste of resources and prevent unnecessary
radiation exposure to patients.
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